We hope that everyone is safe and well and our thoughts go out to all of our contacts across the world during this difficult time.

At PTEN Research we are dedicated to the discovery and development of treatments for PHTS. We support, fund and facilitate research and bring together a global network of PHTS-focused experts.

Whilst we expect some of our activities to be impacted by the outbreak of COVID-19, we are actively supporting all of our grant holders and researchers to progress their work where they can.

Thank you for continuing to support us.

The PTEN Research Team

If you would like to read more about us please visit our website or email us at contact@ptenresearch.org

PHTS YOUNG INVESTIGATOR AWARD FELLOWSHIP

PTEN Research Foundation are delighted to be supporting the PHTS Young Investigator Award Fellowship in conjunction with the Developmental Synaptopathies Consorciium (DSC) and the Rare Diseases Clinical Research Network (RDCRN).

This fellowship is intended to encourage new research into PHTS by early career researchers, focusing on the natural history, development, and treatment of the disease.

The fellowship is open to scientists with a background in PTEN and PHTS, interested in modeling brain cell function and dysfunction, improving the understanding of the natural history, developing clinical guidelines for the care of children with PHTS and developing measures to understand the effect of therapies in clinical trials.

The closing date for applications is Thursday 1st October 2020.

For more information on this fellowship, including eligibility criteria and how to apply, please visit the RFA website here.

MEET OUR GRANT RECIPIENTS!

At PTEN Research we fund projects with leading experts in the field of PHTS at institutions around the world. It is through this approach that we generate the most valuable scientific research with the leading scientists in the field. Our formal application and external review processes ensure we only fund work of high scientific value.

If you would like to find out more about how we fund research or apply for a research grant please here!

We are delighted to announce that Rafael Pulido from the Biocruces Bizkaia Health Research Institute in Spain has been awarded a PTEN Research Foundation Seed Funding Grant to develop and characterise research tools (antibodies) to better understand the biology of PTEN and consequences of PTEN mutation.

It is hoped that this research will provide PTEN and PHTS researchers with better tools to understand the role of PTEN in cells and how and why mutations in the PTEN protein have the consequence they do.

One of the main objectives of the PTEN Research Foundation's strategy is in the area of drug repurposing. This is where we aim to identify therapeutic opportunities for PHTS through the discovery of new applications for drugs that have already been developed to treat conditions such as organ transplant, cancer, lung disease (chronic obstructive pulmonary disease) and inflammation.

In addition to collaborations with academic researchers that enable the evaluation of drug candidates in the context of some of the specific aspects of PHTS (e.g. vascular malformations, cancer progression), we are establishing research agreements with Contract Research Organisations (CROs) to support drug repurposing studies in the areas of neuroscience (e.g. autism spectrum disorder (ASD), PTEN function and regulation).

We plan to have a number of CRO-based projects in progress by August of this year and hope to discover new opportunities for clinical research.

We are delighted to announce that, working with patients, we have been able to support this important work.

Dr Rafael Pulido and his team at the Biocruces Bizkaia Health Research Institute in Spain were awarded a PTEN Research Seed Funding Grant to develop and characterise research tools (antibodies) to better understand the biology of PTEN and consequences of PTEN mutation.

It is hoped that this research will provide PTEN and PHTS researchers with better tools to understand the role of PTEN in cells and how and why mutations in the PTEN protein have the consequence they do.

NEWS AND EVENTS

One of the main objectives of the PTEN Research Foundation's strategy is in the area of drug repurposing. This is where we aim to identify therapeutic opportunities for PHTS through the discovery of new applications for drugs that have already been developed to treat conditions such as organ transplant, cancer, lung disease (chronic obstructive pulmonary disease) and inflammation.

In addition to collaborations with academic researchers that enable the evaluation of drug candidates in the context of some of the specific aspects of PHTS (e.g. vascular malformations, cancer progression), we are establishing research agreements with Contract Research Organisations (CROs) to support drug repurposing studies in the areas of neuroscience (e.g. autism spectrum disorder (ASD), PTEN function and regulation). We will then work with them to further understand the impact of PTEN mutations on cellular responses.

We plan to have a number of CRO-based projects in progress by August of this year and hope to discover new opportunities for clinical research.

Members of the PTEN Research Team attended the 10th European Conference on Rare Diseases & Orphan Products (ECRD) which was held online on the 14th and 15th of May.

The ECRD is recognised globally as one of the largest, patient-led rare disease events and included a number of interesting sessions on the use of technology and role of patients.

Thank you for your interest in and support of PTEN Research, and for taking the time to read our newsletter.

PTEN Research
Registered charity number: 1173589
3rd floor, Paternoster House
65 St Paul's Churchyard
London EC4M 8AB

PTEN Research is committed to ensuring your data is safe and secure. To find out more please visit our privacy policy.

You are receiving this email because you signed up to receive our newsletter. If you would like to be removed from our mailing list, please click the ‘unsubscribe’ link below:

Unsubscribe